Archives
-
The “o2h human health KI EIS fund” makes an investment into Neurocentrx 12 May, 2022
-
The “o2h human health SEIS fund” makes an investment into Neucruit 18 February, 2022
-
o2h Ventures makes a follow-on investment into Oxford Drug Design 18 February, 2022
-
o2h Ventures makes an investment into Xploro from “the o2h human health SEIS fund” 16 February, 2022
-
In4Derm raises £1.6m pre-Series A funding to support its growing pipeline of first-in-class anti-inflammatory and orphan disease therapeutics 03 November, 2021
-
o2h Ventures “Human Health SEIS Fund” Invests into Sanome… 07 October, 2021
-
o2h Ventures portfolio company Small Pharma Successfully Completes Phase I Clinical Trial of DMT-assisted therapy 22 September, 2021
-
o2h Ventures backed Arecor enters into an exclusive formulation collaboration with Intas Pharmaceuticals 08 September, 2021
-
o2h Ventures backed In4Derm enters into an exclusive license agreement with VYNE Therapeutics 13 August, 2021